OncoMatch/Clinical Trials/NCT06574880
STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer
Is NCT06574880 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Lu-PSMA-617 for malignant neoplasm of prostate.
Treatment: Lu-PSMA-617 — The goal of this clinical trial is to is to investigate if it is possible to lower the chance of cancer reoccurrence and also preserve quality of life by using the drug Pluvicto instead of androgen-deprivation therapy to the usual radiation therapy for advanced local prostate cancer. Participants will receive one dose of Pluvicto, followed by radiation about 6 weeks later. Radiation therapy will be completed in 5 treatments over the period of 2 weeks. A second dose of Pluvicto will be given 6 weeks after radiation is complete. Some participants may also receive a third dose of Pluvicto, and this would be given 6 weeks after the second dose of Pluvicto.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Prostate Cancer
Biomarker criteria
Required: FOLH1 PSMA avid disease on PSMA PET/CT, tumor in the prostate has SUVmax ≥ 10 (SUVmax ≥ 10)
PSMA avid disease on PSMA PET/CT, where the tumor in the prostate has SUVmax ≥ 10
Disease stage
Required: Stage III
Excluded: Stage M1A ABOVE AORTIC BIFURCATION
Grade: Grade group ≥ 4 (Grade group)
Node positive disease on PSMA PET/CT or conventional imaging...cT3a or cT3b by conventional imaging (MRI) or PSMA PET/CT; Grade group ≥ 4; PSA ≥ 40 ng/mL
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: chemotherapy
Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy)
Cannot have received: radiation therapy
Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy)
Cannot have received: antiandrogen
Prior treatment for prostate cancer (incudes chemotherapy, radiation therapy, or anti-androgen therapy)
Cannot have received: head and neck radiation therapy
Prior head and neck radiation therapy
Cannot have received: pelvic radiation therapy
History of prior pelvic radiation therapy
Cannot have received: radionuclide therapy (177Lu-PSMA-617)
Prior treatment with radionuclide therapies, 177Lu-PSMA-617 or other
Lab requirements
Blood counts
Hemoglobin > 10 g/dL; WBC > 3000 / mL; ANC ≥ 1,500 / mcL; Platelets ≥ 100,000 / mcL
Kidney function
Creatinine ≤ 1.5x ULN; eGFR > 50 mL/min (CKD-EPI equation); Participants with eGFR 50-60 mL/min require 99mTc-TPA GFR test and only non-obstructive pathology included
Liver function
Total bilirubin < 2× ULN (≤ 2x ULN, except for participants with known Gilbert's Syndrome ≤ 3x ULN is permitted); AST < 3× ULN; Albumin > 3 g/dL
Adequate organ and marrow function to receive treatment: Hemoglobin > 10 g/dL; WBC > 3000 / mL; ANC ≥ 1,500 / mcL; Platelets ≥ 100,000 / mcL; Creatinine ≤ 1.5x ULN; eGFR > 50 mL/min; Total bilirubin < 2× ULN; Albumin > 3 g/dL; AST < 3× ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University Hospitals Cleveland Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify